DAPT (GSI-IX): Selective γ-Secretase Inhibitor for Notch Pathway and Amyloid Research

Executive Summary: DAPT (GSI-IX), supplied by APExBIO, is a highly selective and potent γ-secretase inhibitor with an IC₅₀ of 20 nM in HEK 293 cells. It blocks the proteolytic processing of amyloid precursor protein (APP) and Notch receptor substrates, resulting in reduced generation of amyloid-β peptides (IC₅₀ = 115 nM in cellular assays) [product]. DAPT modulates Notch signaling, impacting cellular differentiation, autophagy, and apoptosis across various cell types. In vivo, DAPT suppresses tumor angiogenesis and serves as a critical reagent for dissecting Notch-related pathways and exploring therapeutic strategies for neurodegenerative and oncological diseases [Lv et al., 2020]. DAPT's solubility and storage parameters are well defined for reproducible experimental integration.

Biological Rationale

γ-Secretase is a multi-subunit protease complex responsible for the intramembranous cleavage of several type I transmembrane proteins, notably amyloid precursor protein (APP) and Notch receptors. The cleavage of APP leads to the formation of amyloid-β peptides, implicated in the pathogenesis of Alzheimer's disease. Notch signaling regulates cell fate, differentiation, and proliferation, with aberrant activation linked to various cancers and autoimmune disorders. Inhibiting γ-secretase with DAPT allows researchers to directly modulate these fundamental signaling pathways and study their physiological and pathological roles [Lv et al., 2020].

Mechanism of Action of DAPT (GSI-IX)

DAPT (GSI-IX) is a non-peptidic, cell-permeable γ-secretase inhibitor. It binds to the γ-secretase complex and prevents the proteolytic processing of its substrates, including APP and Notch. In HEK 293 cells, DAPT exhibits an IC₅₀ of 20 nM for γ-secretase inhibition [APExBIO product page]. This blockade leads to a reduction in the production of amyloid-β40 and amyloid-β42 peptides in cell-based assays (IC₅₀ = 115 nM). For Notch, DAPT prevents the release of the Notch intracellular domain (NICD), thereby halting downstream gene transcription. This highly specific inhibition enables detailed dissection of γ-secretase–dependent pathways.

Evidence & Benchmarks

• DAPT demonstrates potent γ-secretase inhibition in HEK 293 cells with an IC₅₀ of 20 nM under standard culture conditions (37°C, 5% CO₂) (APExBIO).
• It reduces amyloid-β40 and β42 production with an IC₅₀ of 115 nM in cell-based amyloid precursor protein assays (APExBIO).
• DAPT inhibits proliferation of SHG-44 human glioma cells in vitro in a concentration-dependent manner; 1.0 μM is effective for significant reduction (APExBIO).
• In vivo, daily subcutaneous administration of 10 mg/kg DAPT in Balb/C mice reduces tumor angiogenesis markers (APExBIO).
• DAPT blocks Notch/NF-κB-dependent angiogenesis in critical limb ischemia mouse models as evidenced by decreased expression of angiogenic factors and Notch pathway markers (Lv et al., 2020).

For an in-depth mechanistic analysis, see DAPT (GSI-IX): Strategic γ-Secretase Inhibition, which discusses translational advances and expands on the mechanistic detail provided here.

Applications, Limits & Misconceptions

DAPT (GSI-IX) is widely used in neurodegenerative disease research, notably Alzheimer's disease, to probe amyloidogenic processing and Notch signaling. It supports studies in cancer biology, autoimmune disorders, and cell differentiation due to its impact on Notch and caspase pathways. In critical limb ischemia models, DAPT has been shown to suppress Tβ4-induced angiogenesis by blocking Notch/NF-κB signaling [Lv et al., 2020]. Its use in organoid systems and regenerative medicine is detailed in DAPT (GSI-IX): Advanced γ-Secretase Inhibition in Organoids; this article extends the discussion by focusing on in vivo and disease-specific contexts.

Common Pitfalls or Misconceptions

• DAPT is not a pan-Notch pathway inhibitor: It specifically blocks γ-secretase-mediated cleavage, not ligand binding or receptor expression.
• Not effective in water-based solutions: DAPT is insoluble in water; use DMSO or ethanol with sonication for stock solutions.
• Limited stability in solution: Long-term storage of DAPT solutions leads to degradation; prepare fresh stocks or store at -20°C for up to several months.
• Not all cell types respond identically: Sensitivity varies; empirical titration is required for new systems.
• Does not reverse established amyloid plaques: DAPT prevents new amyloid-β generation but does not dissolve existing aggregates.

Workflow Integration & Parameters

DAPT (GSI-IX) is provided as a solid compound (molecular weight: 432.46). It is soluble at ≥21.62 mg/mL in DMSO and ≥16.36 mg/mL in ethanol (with ultrasonic assistance). It is insoluble in water. Stock solutions should be prepared in DMSO or ethanol and stored at -20°C. Avoid repeated freeze-thaw cycles. In vitro, effective inhibitory concentrations range from 0.1–10 μM depending on cell type and endpoint. In vivo, 10 mg/kg/day via subcutaneous injection is validated for angiogenesis suppression in mouse models. For further practical guidance and troubleshooting, refer to Optimizing Cell Assays with DAPT (GSI-IX). This article clarifies best practices for solution preparation and experimental optimization beyond routine protocols.

Conclusion & Outlook

DAPT (GSI-IX) from APExBIO provides precise, selective control over γ-secretase–dependent signaling, allowing researchers to dissect Notch and amyloidogenic pathways with confidence. Its established potency, specificity, and reproducibility make it a foundational tool in neurodegenerative, cancer, and angiogenesis research. As new models and applications emerge, DAPT remains indispensable for mechanistic studies and translational discovery. For broader applications in regenerative medicine and organoid systems, see DAPT (GSI-IX): Advanced Applications in Corneal Regeneration, which this article updates by providing quantitative evidence from disease models.